查詢結果分析
來源資料
頁籤選單縮合
題 名 | 抗敏合方對過敏性鼻炎臨床療效之研究(1)=Clinical Evaluation of Kang-Min-he-Fang in the Treatment of Allergic Rhinitis (1) |
---|---|
作 者 | 戴志展; | 書刊名 | 中醫藥年報 |
卷 期 | 24:1 民95.10 |
頁 次 | 頁53-73 |
專 輯 | 中醫藥療效評估之研究 |
分類號 | 413.52 |
關鍵詞 | 過敏性鼻炎; 抗敏合方; 細胞激素; Allergic rhinitis; Kang-min-he-fang; KMHF; Cytokine; |
語 文 | 中文(Chinese) |
中文摘要 | 過敏性鼻炎是一種非常常見的疾病,據估計,在美國影響近1/10的美國人。臺灣處於亞熱帶地區,因氣候潮濕,罹患過敏性疾病甚多,其中以過敏性鼻炎與氣喘最為常見。近年來,環境污染日益嚴重,過敏性疾病如支氣管氣喘、過敏性鼻炎、濕疹,呈現增加的趨勢,根據調查,20年間(民國63年至83年)臺北地區學童過敏性鼻炎之罹患率顯著增加,民國83年達33.53%,由此可見對過敏性鼻炎治療與預防的重要性。 從細胞激素之調控來看,過敏性鼻炎呈現Th2細胞增多的趨勢,Th2所分泌的細胞激素中IL-4能抑制Th1活性,刺激B細胞生產IgE,刺激肥大細胞生長、發育、誘導血管內皮細胞VCAM-1表現及嗜酸性白血球過多症,相對的,Th1細胞-細胞激素INF-γ對Th2細胞具負迴饋反應。調節Th1/Th2細胞的平衡以使Th2比例減少而Th1比例增加,被認為是治療Th2細胞產生的過敏疾病,因而Th1/Th2免疫調節劑之發展乃為近年來研究對過敏性鼻炎預防與治療之重點之一,免疫療法即是將Th2反應轉向Th1反應,經由其他途徑之免疫療法曾被研究過,經由口腔途徑投與者並沒有成功,因此尋找Th1/Th2細胞平衡的口服藥物是值得開發的方向,抗敏合方(小柴胡湯、逍遙散、六味地黃丸加減),是中醫臨床治療過敏性鼻炎具明顯療效方劑之一,尤其適合臺灣地區過敏性鼻炎證型,但對其詳細之臨床療效評估,與其免疫調節機轉探討一直闕如。本研究擬探討抗敏合方對過敏性鼻炎患者臨床症狀、鼻氣流阻力、鼻腔內空間血清中IgE、過敏原特異性IgE,過敏原特異性IgG4細胞激素(IL-4、IL-5、IL-12、INF-γ)之影響,這是二年之研究計畫,至93年11月已有35位患者進入研究,男20位,平均26歲,女15位,平均23歲,待明年研究完成,解碼後才會有研究結果。 |
英文摘要 | Allergic rhinitis is a common disease that is estimated to affect nearly one tenth of the U.S. population. It is caused by cascade of inflammatory mediators, initiated after contact of the nasopharynx with allergens such as grass, tree pollen, and animal dander. The disease is characterized by chronic nasal symptoms of obstruction, rhinorrhea, sneezing, and itching. Components of inhaled dust, such as mites and molds, or animal dander cause an imtranasal IgE-mediated response in atopic individuals. These perennial allergens active mast cells induce the release of potent chemical medicators that affect inflammatory cells such as eosinophils and basophils, and ultimately produce the signs and symptoms of allergic rhinitis. There are detailed descriptions of the clinical experiences and prescriptions of allergic rhinitis in traditional Chinese medicine. Kang-Min- He-Fang (KMHF) is one of the Chinese herbal medicines used to treat allergic rhinitis. In this study we will evaluate the effect of KMHF on clinical symptoms, serum total IgE, allergen specific IgE, allergen specific IgG4 and cytokines (IL-4、IL-5、IL-12、INF-γ) in the treatment of allergic rhinitis. This is first year of two-year period study, there are 35 patients involved in this clinical trial till now, we will have the result at the end of this study. |
本系統中英文摘要資訊取自各篇刊載內容。